Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POST ETERNAL
2024-513444-28-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ischemic stroke and basilar artery occlusion (BAO) comparing Tenecteplase arm with Alteplase control arm (2 arms). Primary endpoint: Favorable functional outcome at 3 months. Planned start Aug 2026; status: authorised.
02
Drugs
tenecteplasetissue-plasminogen activator
03
Conditions
ischemic strokebasilar artery occlusion (BAO)
Beyond the preview
Go deeper on 2024-513444-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513444-28-00.